Title:
PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST
Document Type and Number:
WIPO Patent Application WO/2019/196803
Kind Code:
A1
Abstract:
Disclosed herein is a pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof useful as an A2A receptor antagonist, and a pharmaceutical composition comprising the same. Also disclosed herein is a method of treating cancer using the pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof as an A2A receptor antagonist.
Inventors:
ZHANG GUOLIANG (CN)
ZHOU CHANGYOU (US)
ZHOU CHANGYOU (US)
Application Number:
PCT/CN2019/081785
Publication Date:
October 17, 2019
Filing Date:
April 08, 2019
Export Citation:
Assignee:
BEIGENE LTD (GB)
ZHANG GUOLIANG (CN)
ZHOU CHANGYOU (US)
ZHANG GUOLIANG (CN)
ZHOU CHANGYOU (US)
International Classes:
C07D487/04; A61K31/519; A61K31/52; A61P35/00
Domestic Patent References:
| WO2012038980A2 | 2012-03-29 | |||
| WO2001092264A1 | 2001-12-06 |
Other References:
SUJAY BASU ET AL.: "Discovery of Potent and Selective A2A Antagonists with Efficacy in Animal Models of Parkinson's Disease and Depression", ACS MED. CHEM. LETT., vol. 8, no. 8, 5 May 2017 (2017-05-05), XP055557887, ISSN: 1948-5875, DOI: 10.1021/acsmedchemlett.7b00175
See also references of EP 3774813A4
See also references of EP 3774813A4
Attorney, Agent or Firm:
WU, FENG & ZHANG (CN)
Download PDF: